![Fenel Eloi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Michael Artinger | M | - |
Cellia Science, Inc.
![]() Cellia Science, Inc. Miscellaneous Commercial ServicesCommercial Services Cellia Science, Inc. develops and commercializes blood cell analyzers that provide rapid, actionable blood cell counts at the point of care. The company was founded in 2021 and is based in Fayetteville, AR. Cellia Science's lead device provides neutrophil and platelet counts for chemotherapy patients at risk of neutropenia and thrombocytopenia, using label-free deep-UV imaging technology exclusively licensed from a third party. The technology will be applied to additional diseases with significant unmet need in the future. Kelly Mabry has been the CEO of the company since 2022. | 2 years |
Kelly Mabry | M | - |
Cellia Science, Inc.
![]() Cellia Science, Inc. Miscellaneous Commercial ServicesCommercial Services Cellia Science, Inc. develops and commercializes blood cell analyzers that provide rapid, actionable blood cell counts at the point of care. The company was founded in 2021 and is based in Fayetteville, AR. Cellia Science's lead device provides neutrophil and platelet counts for chemotherapy patients at risk of neutropenia and thrombocytopenia, using label-free deep-UV imaging technology exclusively licensed from a third party. The technology will be applied to additional diseases with significant unmet need in the future. Kelly Mabry has been the CEO of the company since 2022. | 2 years |
Calvin Goforth | M | - |
Cellia Science, Inc.
![]() Cellia Science, Inc. Miscellaneous Commercial ServicesCommercial Services Cellia Science, Inc. develops and commercializes blood cell analyzers that provide rapid, actionable blood cell counts at the point of care. The company was founded in 2021 and is based in Fayetteville, AR. Cellia Science's lead device provides neutrophil and platelet counts for chemotherapy patients at risk of neutropenia and thrombocytopenia, using label-free deep-UV imaging technology exclusively licensed from a third party. The technology will be applied to additional diseases with significant unmet need in the future. Kelly Mabry has been the CEO of the company since 2022. | - |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
United States | 3 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Fenel Eloi
- Personal Network